000277771 001__ 277771
000277771 005__ 20240229155023.0
000277771 0247_ $$2doi$$a10.1182/bloodadvances.2022008617
000277771 0247_ $$2pmid$$apmid:37477588
000277771 0247_ $$2ISSN$$a2473-9529
000277771 0247_ $$2ISSN$$a2473-9537
000277771 037__ $$aDKFZ-2023-01486
000277771 041__ $$aEnglish
000277771 082__ $$a610
000277771 1001_ $$00000-0003-3116-473X$$aKordelas, Lambros$$b0
000277771 245__ $$aEASIX-1 year and late mortality after allogeneic stem cell transplantation.
000277771 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2023
000277771 3367_ $$2DRIVER$$aarticle
000277771 3367_ $$2DataCite$$aOutput Types/Journal article
000277771 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1695116750_15140
000277771 3367_ $$2BibTeX$$aARTICLE
000277771 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277771 3367_ $$00$$2EndNote$$aJournal Article
000277771 500__ $$a#EA:C060# / 2023 Sep 26;7(18):5374-5381
000277771 520__ $$aPatients with haematological malignancies who survive the first year after allogeneic stem cell transplantation (alloSCT) without relapse have a substantial risk of non-relapse mortality (NRM), and predictive markers are missing. The Endothelial Activation and Stress Index (EASIX) predicts endothelial complications and NRM early after alloSCT. We hypothesised that EASIX assessed 1 year after alloSCT in disease-free survivors may predict late NRM. Relapse-free survivors at one year after alloSCT were retrospectively studied in two independent cohorts (training cohort: n=610, merged validation cohort: n=852). EASIX determined one year after alloSCT was correlated with overall survival (OS), NRM, and relapse. Serum endothelial and inflammatory markers were measured in the training cohort and correlated with EASIX-1y. EASIX-1year predicted OS and NRM but not relapse risk in both, training and validation cohort in univariable and multivariable Cox regression analyses. Brier score and c-index analyses validated the univariable EASIX effects. There was no significant interaction between EASIX-1year and incidence of chronic GvHD on OS. EASIX-1year predicted outcome irrespective of pre-existing comorbidities. Principal causes of NRM in both, training and validation cohorts were infections with and without GvHD, as well as cardiovascular complications. EASIX-1y correlated with sCD141 and interleukin-18, but not with C-reactive protein, suppressor of tumorigenicity (ST)-2, angiopoietin-2, CXCL9 or CXCL8. EASIX-1year is the first validated predictor of late overall and non-relapse mortality. High-risk patients as defined by EASIX-1year might be considered for intensified surveillance and prophylactic measures.
000277771 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277771 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277771 7001_ $$0P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e$$aTerzer, Tobias$$b1$$eFirst author$$udkfz
000277771 7001_ $$aGooley, Ted A$$b2
000277771 7001_ $$aDavis, Chris$$b3
000277771 7001_ $$00000-0002-9767-9739$$aSandmaier, Brenda M$$b4
000277771 7001_ $$00000-0001-5260-1981$$aSorror, Mohamed Lotfy$$b5
000277771 7001_ $$aPenack, Olaf$$b6
000277771 7001_ $$aSchaeper, Nigel Dross Engelbert$$b7
000277771 7001_ $$aBlau, Igor W$$b8
000277771 7001_ $$aBeelen, Dietrich W$$b9
000277771 7001_ $$aRadujkovic, Aleksandar$$b10
000277771 7001_ $$aDreger, Peter$$b11
000277771 7001_ $$aLuft, Thomas$$b12
000277771 773__ $$0PERI:(DE-600)2876449-3$$a10.1182/bloodadvances.2022008617$$gp. bloodadvances.2022008617$$n18$$p5374-5381$$tBlood advances$$v7$$x2473-9529$$y2023
000277771 909CO $$ooai:inrepo02.dkfz.de:277771$$pVDB
000277771 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000277771 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277771 9141_ $$y2023
000277771 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-22
000277771 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-22
000277771 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-22
000277771 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD ADV : 2022$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000277771 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBLOOD ADV : 2022$$d2023-08-25
000277771 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000277771 9200_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000277771 980__ $$ajournal
000277771 980__ $$aVDB
000277771 980__ $$aI:(DE-He78)C060-20160331
000277771 980__ $$aUNRESTRICTED